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The calcitonin gene-related peptide (CGRP) receptor is a complex of a cal-
citonin receptor-like receptor (CLR), which is a family B G-protein-coupled
receptor (GPCR) and receptor activity modifying protein 1. The role of the
second extracellular loop (ECL2) of CLR in binding CGRP and coupling to
Gs was investigated using a combination of mutagenesis and modelling. An
alanine scan of residues 271–294 of CLR showed that the ability of CGRP to
produce cAMP was impaired by point mutations at 13 residues; most of
these also impaired the response to adrenomedullin (AM). These data were
used to select probable ECL2-modelled conformations that are involved in
agonist binding, allowing the identification of the likely contacts between
the peptide and receptor. The implications of the most likely structures for
receptor activation are discussed.1. Introduction
The extracellular loops of G protein-coupled receptors (GPCRs) are important for
receptor function. They contribute to protein folding, provide structure to the extra-
cellular region and mediate movement of the transmembrane (TM) helices on
activation. The secondextracellular loop (ECL2) is of significance for ligandbinding
and receptoractivation [1–3]. In familyB (or secretin-like)GPCRs, it is themost con-
served and often the longest of all the ECLs, and so is in a good position to interact
with the endogenous peptide agonists for these receptors and is in a prominent cen-
tral position to mediate conformational changes [1]. The peptide ligands typically
contain 30–50 amino acids. The family B receptors are characterized by a large
N-terminal domain (approx. 100 amino acids), which interacts with the C-termini
of their cognate peptide ligands [4]. The N-termini of these peptides interact with
the ECLs and the TM region of the receptors resulting in activation [4,5]. ECL2
has been implicated in agonist binding at the GLP-1, secretin and CRF1 receptors
[6–10]. For the GLP-1 receptor, ECL2 plays an important role in directing coupling
towards stimulation of ERK1/2 activation versus Gs and activation of adenylate
cyclase [7]. However, the molecular basis for this observation remains obscure.
Several distinct conformations have been recognized for ECL2 in family A
GPCRs, ranging from the ‘lid’ seen in rhodopsin, which encloses the bound reti-
nal ligand, to the extended sheet seen for most of the peptide GPCRs [11–13].
Movement of ECL2 seems to be important in the activation of family A GPCRs;
this is linked to agonist-induced changes in TM5 and helps propagate these
changes to other parts of the GPCR [11,14].
There is currentlyno crystal structure showinghowapeptideagonist bindsto the
ECLs or TM domain of a family B GPCR. A number of models have been proposed
based on cross-linking and mutagenesis data [8,15,16] but it has proved extremely
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2difficult to accurately predict the ECL conformations by this
approachor bysimulation [17].Given thevariety in familyBpep-
tide sequences [5,17], it seems likely that there is no single mode
of peptide binding to the ECLs of family B GPCRs [18].
We have previously used a combination ofmutagenesis and
computation to produce a model indicating how the TM
domain of the calcitonin receptor-like receptor (CLR) can inter-
act with Gs [19]. CLR is the GPCR component of the calcitonin
gene-relatedpeptide (CGRP) receptor.CGRP ispart of apeptide
family that also includes adrenomedullin (AM), calcitonin and
amylin and is involved in heart disease and migraine [20].
CLR interacts with a single TM protein, receptor activity-
modifying protein 1 (RAMP1), in order to bind CGRP and
also AM [21], though AM interacts with CLR more strongly in
the presence of RAMP2. Using an independent modelling
approach, Wootten et al. [22] have produced a broadly similar
model for the GLP-1 receptor, which indicates how agonists
can activate the receptor by interacting with different TM resi-
dues. Using both mutagenesis and computation is a powerful
strategy for studying the activation of GPCRs [12], especially
given that structural techniques for instance crystallography
give static pictures ofwhat is fundamentally a dynamic process.
In previous work, we have examined the role of the first and
third ECLs (ECL1/3) of the CGRP receptor. However, only a
small number of residues within ECLs 1 and 3 were implicated
in CGRP binding [18]. Consequently, we have now addressed
the role of ECL2 in this receptor. In an extension of the strategy
used toexamine theTMresiduesofCLR,wehaveexperimentally
identified CLR residues that reside within the last turn of TM4,
ECL2 and the first turn of the turn of TM5 and that are key for
CGRP and AM interactions with the CGRP receptor. We have
then used all of our data for each ECL and the TM domain, in
combinationwith heuristic loopmodelling,molecular dynamics,
docking and sequence analysis to model the interaction between
theN-terminus of theCGRPpeptide andCLR, based on amodel
of the Gs-coupled state of the CGRP receptor.2. Material and methods
2.1. Preparation of mutants, transfection, receptor
expression and radioligand binding
The preparation of mutants and molecular biology was as descri-
bed earlier [23]. An HA-tagged CLR construct was used to allow
measurement of cell surface receptor expression by ELISA [20,23].
Mutants were transfected into Cos 7 cells using PEI [20,23]. Radio-
ligand binding was carried out on cell membranes using [125I]
iodohistidyl-human alpha CGRP (Perkin Elmer) [20,23].
2.2. Measurement of cAMP
For the investigation of CGRP-mediated activation of the recep-
tor, cAMP was measured using a FRET-based PerkinElmer
LANCE cAMP 384 kit according to manufacturer’s instructions.
Briefly, transfected cells were removed from the plate with trypsin
EDTA, washed with phosphate-buffered saline and resuspended
in assay stimulation buffer (SB; phosphate-buffered saline þ 0.1%
(w/v) bovine serum albumin þ 0.5 mM isobutylmethylxanthine).
Cells were counted with a haemocytometer and the appropriate
cell number resuspended in SB þ 1/100 AlexaFluor 647-anti
cAMP antibody at an assay concentration of 2000 cells/10 ml. A
total of 2000 cells/well were loaded onto a 96-well white Optiplate
(PerkinElmer) and were concentration-dependently stimulated in
triplicate with a logarithmic increase of CGRP diluted in SB from1026 to 10212 M with SB as a basal point. The plate was incubated
in the absence of light for 30 min at room temperature before
20 ml/well of detection mix was added. The plate was incubated
in the absence of light for a further 60 min. FRET was recorded
by excitation at 320 nm and emission at 665 nm. The experimental
pEC50 values for wild-type (WT) receptor in the electronic sup-
plementary materials, table S1 show some variation, reflecting
differences in coupling efficiencies between cells as the data were
collected in excess of ayear. Suchdrift has beenobservedpreviously
withCGRPreceptors [24,25]. To control for this, a paireddesign-test
was used so that each mutant was compared in the same exper-
iment against a corresponding WT control. For the investigation
of AM-mediated stimulation of the CGRP receptor, cAMP was
measured with alphascreen, as described previously [26]. Data
were normalized against the maximum fitted response for CGRP
or AM; basal cAMP was taken as the fitted minimum.
2.3. Data analysis
Curve fitting was done with GRAPHPAD PRISM 5 or 6 (GraphPad
Software Inc., San Diego, CA, USA). Both this and statistical
analysis were as described previously [20].
2.4. CLR models
The starting point for the models indicating the interaction
between CGRP and ECL2 was a recent model of the active state
[19]. The most appropriate X-ray crystal structure model for a
fully active GPCR is that of the b2-adrenergic receptor (b2-AR)
coupled to Gs [27], which is similar to the b2-AR nanobody stabil-
ized [28] and the rhodopsin active structures stabilized by a
C-terminal peptide from transducin [29,30]; these active structures
are characterized by the outward tilt of the intracellular end of TM6
that is necessary for G protein binding. In the absence of G protein
or G protein-derived peptides, X-ray crystal structures of agonists
bound to GPCRs stabilize substates that are not too different to the
inactive form [31], i.e. they lack the outward tilt of TM6; in such
agonist-bound structures, the conformation of Y5.58 is taken to be
indicative of the state because in the inactive form, it usually inter-
acts with L1.63 and L8.50, whereas in the active substate, it stabilizes
the active conformation of R3.50. Our active structures are stabilized
by the Gs C-terminal peptide (R373-L394), and hence included the
outward tilt of TM6 [27]. Nevertheless, the conformation of Y5.58
(and the tilt of TM6) was monitored to check that active state char-
acter was maintained as fully as possible and that the simulations
could be terminated should the active structure begin to acquire
inactive character. The underlying alignment was based on a
novel approach to the class A–class B alignment, aided by a
GCR1/class E alignment that was used as a bridge between the
class A and class B sequences. This has been repeated using
improved methodology but the alignment remains unaltered
[32]. The status of GCR1, GCR2 and other putative plant GPCRs
has been questioned [33–35], but GCR1 has all the features
expected for a GPCR fold [32], while GCR2 was predicted [36]
and later shown to be a lanbiotic cyclase [37]. The simulations
that underlie the CLR modelling [19] were extended to 100 ns
(see the electronic supplementary material).
To model the peptide binding, disulfide-bonded cyclic
CGRP1–7 was constructed in Maestro and docked to the active
CLR model (after 80 ns, i.e. just before the first signs of the onset
of inactive character; [19]) using Glide SP [38,39], as described in
the electronic supplementary material. The best-scoring pose was
verified by sequence analysis, as described below. The CGRP
extension (up to residue 32) was modelled onto CGRP1–7 using
the NMR solution structure of salmon calcitonin (PDB code 2glh)
[40], using the alignment of Watkins et al. [5].
In the molecular dynamics simulations, the active structure
begins to acquire some inactive character after 80 ns (i.e. F7.53
switched towards the inactive conformation; see the electronic
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Figure 1. Effect of mutations on the pEC50 for AM (white bars) and CGRP (grey bars) at cAMP production. The difference in mean pEC50 between the mutant and
WT receptor is shown, hence a negative value shows a decrease in potency. Where there was no detectable stimulation of the mutant by peptide (#), an arbitrary
value of –3 has been shown in the figure. Data are shown in the electronic supplementary material, table S1. *p, 0.05, **p, 0.01, pEC50 of mutant
significantly different from that of WT by paired Student’s t-test or repeated measures ANOVA followed by Dunnett’s test as appropriate.
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3supplementary material, figure S1). This is well before it would
be possible to fully sample the loop conformations, despite high
principle components for ECL2 residues; see the electronic sup-
plementary material, figure S1D. Thus, given that the MODELLER
scoring functions are approximate, we have taken a heuristic
approach to determining theECL2 conformation.Wehave therefore
generated and refined100 independent loop conformations; suitable
conformations were selected if key loop residues identified by the
mutagenesis interacted with CGRP or AM to within a cut-off of
5.5 A˚. There are many assumptions inherent in this approach, as
discussed below in §3.2.5; this is apparent because it was impossible
to generate conformations where each significant ECL2 residue
interacted with CGRP. Thus, multiple conformations of ECL1 (resi-
dues 202–212), ECL2 (residues 274–293) and ECL3 (residues
353–363) were simultaneously generated in the presence of
CGRP1–32 usingMODELLER [41–43]. Each conformation is character-
ized by its DOPE score; a lower score corresponds to a more likely
conformation. AM binding to CLR was similarly modelled by sim-
ultaneously mutating CGRP to AM and generating the loop
conformations within MODELLER.
2.5. Sequence analysis
The sequences of CGRP and amylin (which binds to the calcito-
nin receptor (CTR)) from several species were aligned [5,44]. The
sequences of amylin and CGRP and the sequences of CTR and
CLR were analysed in parallel to identify mutations that are cor-
related between the CTR–amylin and CLR–CGRP systems, with
a view to identifying contact points.
2.6. Residue numbering
For amino acids within the proposed ECLs of CLR, only the resi-
due numbers are shown. For residues that are within the TM
helices of CLR, a superscript denotes their position using an adap-
tion of the Ballasteros–Weinstein numbering proposed elsewhere
[19]. The peptide residue numbers are given as superscripts.3. Results and discussion
3.1. Experimental analysis of the CGRP receptor
In this section, the results of an alanine scan of the CGRP
receptor will be presented. The implications of these data
will be discussed alongside the modelling in §3.2.3.1.1. Effects of alanine substitution on CGRP-mediated cAMP
production
Twenty-four individual residues of CLR ECL2 from A271
to I294 were mutated to alanine (alanine residues were
mutated to leucine) and their ability to respond to CGRP
and stimulate cAMP production was investigated when co-
expressed with human RAMP1. These residues were selected
as they are most likely to incorporate the whole of ECL2 and
approximately one turn of helices 4 and 5 immediately adja-
cent to the loop, based on our previous analysis [19].
Figures 1 and 2 and the electronic supplementary materials,
table S1 and figure S2 show that the pEC50 values of 14 of
the 24 mutants were significantly different to WT, indica-
ting that ECL2 is particularly important for CGRP receptor
function. Seven mutants resulted in significant cAMP reduct-
ion of more than 10-fold. These are R274A, Y278A, D280A,
C282A, W283A, I284A and T288A. Of the remaining seven
mutations, N281A showed a small increase in potency and
six mutants had small but significant reductions in pEC50.
Y292A and I294A showed significant but small increases
in maximal cAMP response (Emax) (see the electronic
supplementary material, table S2).3.1.2. Cell surface expression of receptors and CGRP binding
Owing to the likelihood of attenuated binding of CGRP, radio-
ligand binding could not be reliably used to provide an
estimate of receptor expression for these constructs. Accord-
ingly, an ELISA to measure receptors at the cell surface was
used (see the electronic supplementary materials, table S3).
All of the mutants were expressed at the cell surface to
within approximately 60% of WT levels. Reductions to this
level of expression has been previously shown to have little
effect on the potency of CGRP-mediated cAMP signalling for
this or CTR expressed in Cos 7 cells [45,46] and in this study,
there was only a very low correlation between expression
and pEC50 (r
2 ¼ 0.23). Mutated receptors that had large
impairments of cAMP production were examined for their
ability to bind CGRP using a radioligand-binding assay (see
the electronic supplementary materials, table S4). All of the
mutants examined, except Y277A had reduced affinity for
the radioligand.
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43.1.3. Effects of alanine substitution on AM-mediated
cAMP production
The CGRP receptor also acts as a functional AM receptor with
an affinity of approximately 10-folds less than that for CGRP
[47]. To explore the effects of the above mutants further, their
ability to respond to AM through cAMP production was sub-
sequently investigated. The majority of the effects were in line
with those seen with CGRP (figure 1 and the electronic sup-
plementary material, table S2), the most notable differences
being the lack of effects of AM at Y277 and Y278 and for
some mutants, it was impossible to measure any activation
of the receptor (figure 3). In the case of R274A, W283A and
D280A, the response was so low that an Emax could not be
reliably determined. There was especially good agreement
between the two agonists for the central area of functional
importance ranging from D280 to T288. As with CGRP,
many of these alanine substitutions reduced AM potency.The effect of mutations at the N- and C-termini of ECL2 was
more variable between the two peptides. At the N-terminus,
the CGRP-affecting mutants Y277A or Y278A did not show
AM-mediated effects on pEC50. However, there were approxi-
mately 25% reductions in the maximal cAMP response. At the
C-terminus of ECL2, the two leucine mutants (L290A and
L291A), which showed a reduction in potency with CGRP,
were not significantly affected when stimulated with AM.
3.1.4. Basal activity
In the investigation of CGRP (with Cos 7 cells from a UK
source and measuring cAMP with a LANCE assay), N281A
and I294A showed a significant increase in basal cAMP
signalling (i.e. constitutive ligand-independent signalling acti-
vity; see the electronic supplementary material, table S2).
These values increased by 9.9+ 0.9% and 21.8+2.9%
above WT, respectively. When the cells were investigated
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5for AM responsiveness (using Cos 7 cells from a New Zea-
land source and Alphascreen), small but statistically
significant elevations were noted for A273L, Y277A and
I284A but not N281A and I294A. Thus, the increase in
basal cAMP depended on experimental conditions and was
always small. In the course of analysing over 200 mutants
of CLR [19,20,48], we have observed very few that showed
elevated activity, possibly indicating that there are multiple
locks in place to keep the receptor in an inactive form; it is
possible that the RAMPs might contribute to this.3.1.5. The importance of the ECL2–TM3 disulfide linkage
As C282 is predicted to form a disulfide bond with C2123.25
[19], further mutagenesis was used to explore this, using
CGRP as the agonist. The mutant C212A impaired cAMP pro-
duction in much the same way as C282A (pEC50 values: WT9.62+0.76, C212A 8.10+0.43, n ¼ 3, p, 0.05, Student’s
t-test); however, the double mutant C212AC282A showed
a WT response (pEC50 values: WT 9.49+0.11 n ¼ 3,
C212AC282A 9.41+0.09, n ¼ 3), thus implying that the disul-
fide bond itself is not crucial for CGRP binding or signalling.3.1.6. The importance of the ECL2/TM5 junction
As noted above, L290A and L291A both showed small but
significant reductions in CGRP potency. As movements
at the top of TM5 have been implicated in the early stages
of activation of the b2-AR and rhodopsin [11], the role of
residues in this region was probed by further mutagenesis.
The individual reduction in EC50 values for L290A (approx.
eightfold) and L291A (approx. fourfold) was highly exacer-
bated by an L290AL291A double mutant that reduced the
EC50 by approximately 500-fold compared with WT (WT
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6pEC50 10.6+0.11, L290AL291A pEC50 7.93+0.13, n ¼ 3,
p, 0.01, Student’s t-test).3.2. Modelling of ECL2 and interactions with CGRP
and AM
3.2.1. Analysis of the MODELLER-generated ECL2 conformations
The loop conformations spanned a large proportion of the
space available to ECL2 (figure 4a). The analysis of the full
set of interactions for all loop conformations is given in
figure 4b,c. Although this analysis includes high-energy con-
formations, it is interesting as it highlights general interaction
preferences of several amino acids in CGRP and ECL2. ECL2
forms an extended loop; this conformation is often seen as
two antiparallel beta-strands in all peptide GPCRs for which
structures are available, creating a large interface forpeptide–receptor contacts [12]. Here, we re-interpret several
previously reported experimental observations that were
made in the absence of a modelled structure [44] and that
are consistent with our models. D3 of CGRP in our model is
not in a constrained pocket, hence it makes few interactions
with ECL2; indeed this position can accommodate a photo-
affinity probe [44]. The fact that it can be readily replaced by
arginine in the AM model provides further justification for
our model. By contrast, A5 of CGRP is sterically constrained
and indeed makes a relatively large number of interactions
(figure 4c), showing that it has many close neighbours. T6 is
discussed in more detail below; here, the preferred interactions
are to T288. In several loop conformations, T9 of CGRP inter-
acts with polar residues such as D280, D287 and T288. There
is some indirect evidence that H10 may also be part of this net-
work that responds to negative charges [44]. L15 of CGRP can
be replaced by a large benzoyl-phenylalanine moiety with
Table 1. Data used to select loop conformations.
CLR residues CGRP effect AM effect
A273
p p
R274
p p
Y277
p
Y278
p
D280
p p
C282
p
W283
p p
I284
p p
S285
p p
D287
p
T288
p p
L290
p
L291
p
Figure 5. The highest scoring docked pose of CGRP1– 7 (mauve). Resides A
1
and T6 reside close to Ala203 and Thr288, respectively (blue). The CGRP dis-
ulfide bond is shown in yellow. The loop conformation shown here for ECL2
was a high scoring (i.e. favoured) conformation. TM7 is shown as transparent.
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7only small changes in affinity (it makes few interactions to
ECL2); however, replacement of L12 of CGRP causes around
a 10-fold decrease (it makes more interactions with ECL2)
[44]. Replacement of R18 of CGRP by alanine has virtually
no effect, and indeed it makes few interactions, but the
double alanine mutant R11AR18A shows 100-fold reduction
in affinity [44]. Replacing either of these arginine residues
with glutamate caused over a 10-fold reduction in affinity;
but replacement with glutamine led to retention of high affi-
nity binding [24,25,49], presumably because glutamine can
still donate hydrogen bonds. Indeed, we see that both D280
and D287 are able to interact with R11, but as D287 is less sig-
nificant for AM (where K substitutes for R11), it is more likely
that D280 is the preferred partner to R11, even though D287
makes more interactions. CGRP residues 1, 4, 8, 13 and
beyond are predicted to make few, if any contacts with
ECL2; this is consistent with the known structure activity
relationships for CGRP where they seem to be of only minor
importance [44]; this observation justifies the orientation of
the helical extension to CGRP1–7.
W283 and I284, which reside in the centre of ECL2, make
the most interactions; these are either to the region around
R11 or to the N-terminal region (see below).
Having analysed the pattern of interactions over all loop
conformations, we see that this pattern is consistent with
known experimental data on the CGRP peptide [44] and so
we can now seek to identify preferred conformations and
interactions from the mutagenesis data given in table 1,
which indicates the most important residues for CGRP or
AM binding.
The residue that is the equivalent to position 6 in CGRP is
conserved as threonine in all members of the CGRP/CT/
AM/amylin family of peptides and is essential for CGRP
agonist activity [44,50]. Sequence analysis shows that the
most likely candidates that are (i) conserved in CLR and
CTR and (ii) able to donate or accept an H-bond are in
ECL2 where D280, D287 and T288 are the best candidates.
As D280 makes few interactions to T6 (see above) and D287
is not significant in AM binding (figure 1) and is of moderate
importance in CGRP activation, it would seem that T288 is
the most promising candidate.Figure 5 shows that the best-scoring docked conformation
of CGRP1–7 satisfies the T
6 criteria (by interacting with D280/
D287/T288) in the presence of a sample ECL2 conformation
(figure 4), and that D3 is not in a sterically crowded region
(see also figure 4c). This indicates that the docked CGRP1–7
has provided a suitable template for modelling the full
CGRP peptide and hence modelling the conformations of
ECL2. In the docked conformation, A1 of CGRP is not only
close to A203 of ECL1 of CGRP, but also able to accommo-
date N-terminal extensions. As discussed in the electronic
supplementary material, this is consistent with mutagenesis
and bioinformatic analysis of CGRP and AM binding.3.2.2. Filtering the ECL2 conformations
The number of interactions made by key ECL2 residues
(table 1) to CGRP for each of the 100 loop conformations
are displayed in figure 4b (y-axis). The ideal loop confor-
mation should make an interaction between T6 of CGRP
and D280, D287 or T288, have a large negative DOPE score,
make a high number of key interactions and ideally have
W283 in a vertical orientation (see below). The majority of
conformations, denoted by a grey cross in figure 4b, do not
make an appropriate interaction with T6 and are discarded.
Several conformations make 6–9 interactions, including
those to T6 via D280, D287 or T288. Because interactions to
D280, D287 or T288 are observed in the top 15% of the most
energetically preferred conformations and because the DOPE
score is an empirical rather than a rigorously accurate score,
it is not advisable to use energy (i.e. the DOPE score) as the
sole criteria to identify the preferred binding mode, hence
the importance of filtering the loop conformations using the
mutagenesis data. Only one conformation (conformation 34,
top left of figure 4b) records a direct interaction with R2744.64,
for either CGRP or AM, but this interaction is to R11 of CGRP
and the distance is long; closer inspection shows that D280
bridges between R2744.64 and R11 of CGRP. Several other
conformations of R2744.64 act in this way, and could help to
orientate a D280-R11 interaction. Thus, a direct interaction
betweenCGRPand R2744.64 is probably an unrealistic selection
criterion. R2744.64 is highly conserved as arginine or lysine
across the class B GPCRs; mutation in the GLP-1 and secretin
receptors also impairs function [6,7,51]. It is possible that
the positively charged head group may also interact with the
phospholipid bilayer [52].
Based on the data in figure 4b (and similarly for AM inter-
actions with the CGRP receptor which altered pEC50), we
selected six conformations for CGRP and seven for AM (see
the electronic supplementary material, figure S4). Apart from
one CLR/CGRP structure (conformation 34), these all have a
similar conformation for ECL2. However, despite a similar
(a)
(b)
(c)
Figure 6. The interactions in the high scoring models for CGRP model. The
interactions include D280 with H10 and R11, T288 with T6 (and A5), S285 with
A5 and D287 with A5 (shown in (b); the ECL2 hydrophobic residue interactions
include W283 with D3 and T4 as well as residues on TM2 and TM3, and I284
with A5. (b) Hydrogen bonds between significant ECL2 residues include R274
interacting with Y277 and D287 (close to A5) interacting with Y278, which
seem to stabilize the ECL2 fold. (c) The remaining significant ECL2 residues,
namely A273, L290 and L291; A273 and L291 do not interact with CGRP,
L290 interacts with L12 in some ECL2 conformations while L291 points
towards TM7, but could also affect the RAMP interaction; it is notable
that most of these non-interacting residues plus Y277 and Y278 are not sig-
nificant in the binding of AM and so it is likely that in CLR they are important
in RAMP1-directed indirect effects on the binding. These structures have not
been refined by molecular dynamics simulations for reasons discussed above
and so the molecular information should not be overinterpreted.
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8ECL2 conformation, there are differences in the orientations of
the W283 side chain, and only one high scoring CGRP and one
high scoring AM conformation have W283 in a vertical orien-
tation (a range of W283 interactions is shown in the electronic
supplementary material, figures S4 and S5). The preferred
CGRP structure (figure 6) satisfies 6/13 of the mutagenesis
results given in table 1,whereas theAMmodel (see the electronic
supplementary material, figure S6) satisfies 4/7.3.2.3. The orientation of W283
The loop generation alone does not help to address the
orientation of W283 as it interacts with CGRP in most confor-
mations of ECL2. However, the docking raises an interesting
question with regard to the site-directed mutagenesis data on
TM2 and TM3, as shown in the electronic supplementary
material, figure S7. A number of residues on TM2 and TM3
(namely T1912.57, L1952.61, V1982.64, A1992.65 and H2193.32)
show reduced cAMP production on mutation [19]. In ourmodel, CGRP can interact with L1952.61, V1982.64, A1992.65
but not T1912.57 and H2193.32 because they lie too deeply
within the helical bundle. If CGRP were positioned to interact
with these residues, it would then most likely not satisfy the
interactions of A1 and T6. The alanine-substitution effect at
T1912.57 and H2193.32 may instead result from interactions
with W283 of ECL2 as suggested by analysis of inactive
CLR simulations and selected high scoring loop conforma-
tions (figure 6; see the electronic supplementary material,
figures S5–S7). The hydrophobic patch of L1952.61, V1982.64
and A1992.65 on TM2 is important in CLR for CGRP-
mediated activation of cAMP production [20] but while this
region is more polar in some GPCRs, alternative hydrophobic
regions reside nearby in other family B GPCRs where W283
could bind. Consequently, we prefer the vertical confor-
mation of W283 as no other conformation satisfies the
mutation data on T1912.57 and H2193.32.3.2.4. AM binding
Our models can also explain the mutagenesis data for AM-
mediated activation of the same receptor. It is proposed
that AM sits in a very similar orientation to CGRP in the pre-
sumed binding pocket (see the supplementary material) but
accesses a slightly different subset of ECL conformations.
There are no direct interactions with R2744.64, Y277 and
Y278, but in the case of CGRP, the model suggests that
there are also few, if any, direct interactions with these
residues and instead they work primarily to stabilize pro-
ductive conformations of ECL2. In the case of CGRP, we
suggest that the consequence of this is to strengthen the inter-
actions between the contact points between the peptide and
ECL2 and so enhance potency. AM probably makes fewer
contacts with ECL2; RAMP2 may be required to generate a
full complement of interactions with this loop.3.2.5. Implications for receptor activation
The binding of an agonist has to stabilize an active confor-
mation of the receptor, increasing the activity of effector
proteins. For the CGRP receptor, the best characterized inter-
action is with Gs, leading to the production of cAMP and,
based on homology with the active crystal structures of rho-
dopsin and the b2-AR and extensive mutagenesis, we
produced a model of how this can take place [19]. Based on
the current data, it is possible to make some broad points
in regard to possible agonist activation mechanisms in CLR.
A change in the C-terminal region of ECL2 could easily be
propagated to TM5 and changes in this helix that are linked
to movement of TM6 have been identified as one of the ear-
liest steps leading to receptor activation in family A GPCRs
[11,53]. It may be significant that T6 of CGRP, important for
agonist activity in both CGRP and AM [44,50], is in close
proximity to the C-terminal region of ECL2 where D287 or
preferably T288 are its most likely interaction partners.
Further support for an important role of TM5 in receptor acti-
vation comes from the disrupting effect of the double mutant
of L220/L221A. A shift in TM5 in CLR could subsequently
allow movement of TM6. In family B GPCRs, there is a con-
served proline residue in TM6, which is likely to produce a
kink [23] analogous to the situation found in family A
GPCRs, so displacement of TM6 will lead to the opening of
a G protein-binding pocket between it and TM3 [11].
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9The conserved N-terminal part of ECL2 [1] links ECL2 not
only with TM4 but is also likely to influence ECL1 and hence
TM2 and 3. While ECL1 is of only minor importance in the
binding of CGRP, residues just below it in TM2 and
H2193.32 of TM3 are of considerable significance for receptor
activation [20]. Similar clusters are not obvious in the upper
regions of the other TMs [19], although systematic mutagen-
esis is needed to test this. These residues at the tops of TM2
and 3 may be in a position to make contacts with residues
at the base of ECL2, such as W283 and I284 as proposed
in this study (see the electronic supplementary material,
figure S7). Thus, CGRP has the potential to influence TM2
and 3 both directly and indirectly via ECL2. In family A
GPCRs, TM3 is of particular importance for receptor acti-
vation partly owing to its angle of tilt across the TM bundle
linking different parts of the bundle together. TM3 also con-
strains the C-terminal end of TM6 in at least some receptors
via an ionic or polar lock [11,54]. In family B GPCRs, the
equivalent of the ionic lock is probably a set of polar inter-
actions involving residues at the C-terminal ends of TMs 2,
3 and 6 [19,22,55]; there are further interactions involving a
polar network in the mid-regions of TMs 2, 3 and 7
[19,22,56]. Any interaction with TMs 2 and 3 is likely to
play a key role in the activation of a family B GPCR.
The model developed for CGRP binding is therefore con-
sistent with what is known about how CGRP activates its
receptor, although it is speculative. It is also important to
note that we have interpreted the effects of the mutations
directly on the conformation of ECL2 itself. We cannot rule
out that some of the effects may be on the TM bundle or extra-
cellular domains of CLR or even of the RAMP. The data can be
used to address these issues more fully once a crystal structure
of the active CLR/RAMP1 complex becomes available.4. Conclusion
We have evaluated the role of ECL2 in the binding of both
CGRP and AM to the CGRP receptor and have interpreted
the results by means of molecular modelling. The study indi-
cates that ECL2 is particularly important for the interaction ofCGRP with its receptor involving 13 ECL2 residues in the
loop out of 24 residues studied. By contrast, only two resi-
dues in ECL1 and one in ECL3 influence the interaction of
CGRP with its receptor [19,20]. Within ECL2, R274, W283,
D280, D287 and T288 are of particular importance. We have
suggested mechanisms where binding to this loop causes
changes to the extracellular ends of TMs 2, 3 and 5, which
in turn can be linked to movements of the cytoplasmic ends
of TMs 3, 6 and 7, to allow G protein binding and activation.
While ECL2 appears to be involved in the binding of many
peptide agonists to family B GPCRs, its precise role is probably
receptor and ligand dependent. Models have been produced
based on either mutagenesis or cross-linking data for the bind-
ing of secretin, GLP-1, VIP and PTH to their receptors
[8,15,16,57,58]. While there are of course limitations to any
modelling study, it is striking that there is no agreement as to
the mode of binding. In the case of some models developed
for GLP-1, secretin and VIP, their N-termini penetrate more
deeply to interact with TM2, providing a more direct method
of altering the conformation of both this helix and probably
the adjacent TM3 during the process of receptor activation.
While GLP-1 may not bind in the same way as CGRP (where
the disulfide bond makes the N-terminus more bulky), a
study of this receptor has provided the clearest evidence yet
that ECL2 is an important determinant of signalling specificity
[6,7]. Even in possession of crystal structures, the flexible nature
of ECLs requires studies such as this to shedmore light on how
GPCRs respond to peptide agonists. Our approach used to
model the interaction between either CGRP or AM and the
receptor may be applicable to other GPCRs. The full set of
structures is available from ftp.essex.ac.uk/pub/oyster/
CLR_ECL2_2013/CLR_ECL2_structures.tar.gz (see also the
electronic supplementary material); these structures compare
favourably to the recent class B X-ray structures of glucagon
and the corticotropin-releasing factor-1 receptors as described
in the electronic supplementary material.
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